Drug Approval | September 02, 2021
Reddy-Lenalidomide launched in Canada
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Arrow is the marketing partner in US
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)